On August 16, 2024, BioNTech SE and Pfizer Inc. reported top-line results from their Phase 3 clinical trial for a combined mRNA vaccine targeting influenza and COVID-19 for healthy individuals aged 18-64.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.